BBC News
00:00 GMT, Wednesday, 10 February 2010

Scientists have found genetic hotspots for bowel cancer they say will help doctors better treat the disease.

They say a third of the 37,500 people diagnosed with the cancer in the UK each year harbours the DNA code that renders common drugs ineffective.

Being able to identify these patients early will mean they can be started sooner on treatments that will work.

The next step, say the authors...

admin

Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations

CNNMoney.com
Source: GLOBE NEWSWIRE

Seliciclib Kills Lung Cancer Cells Addicted to CDK2/Cyclin E; Phase 2 Study in Lung Cancer Ongoing

January 07, 2010: 12:08 PM ET

BERKELEY HEIGHTS, N.J., Jan. 7, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of two peer-reviewed journal articles...

admin

PharmacyEurope
Friday 27th November 2009

The cancer drug cetuximab is to be made available on the NHS across the North East as a third-line treatment for patients with advanced colorectal tumours.

The decision by North of England Cancer Drug Approvals Group (NECDAG) has been made ahead of guidance from the National Institute for Health and Clinical Excellence (NICE).

NICE recently approved cetuximab as a firstline treatment as part of pre-surgery for...

admin

PharmacyEurope
Wednesday 25th November 2009

Cetuximab added to neoadjuvant chemotherapy enables life-saving surgery in patients with liver lesions linked to colorectal cancer, according to a report in The Lancet Oncology.

It says that while removal of colorectal liver metastases is a potential cure, the disease has traditionally been inoperable in up to 80% of patients.

But research now shows that neoadjuvant treatment with irinotecan or oxaliplatin-based...

admin

PharmacyEurope
Monday 9th November 2009

Survival in patients with advanced head and neck cancer is prolonged by adding cetuximab to radiation therapy, according to a report published online first in The Lancet Oncology.

It concludes that as improvement persists for up to five years, it should now be considered as a standard treatment option.

The report notes that most head and neck cancers express the epidermal growth factor receptor (EGFR), and that...

admin